Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
August 2nd, 2024
Tropomodulin 3 (TMOD3) has been increasingly studied in tumors in recent years. This study is the first to report that TMOD3 is highly expressed in ovarian cancer and is closely associated with platinum resistance and immune infiltration. These results could help improve the therapeutic outcomes for ovarian cancer.
Our research focuses on drug-resistant in ovarian cancer. In our paper, we try to uncover the role of TMOD3 in ovarian cancer and chemotherapy. Many cytos calendar proteins have been demonstrated to play important role in ovarian cancer and drug resistance, but there are still no reports on the role of TMOD3, ovarian cancer and sim therapy.
Our study first reported that TMOD3 is highly expressed on ovarian cancer, and closely associated with platinum resistance and immune infiltration. This result contributed to the improvement of therapy outcomes in ovarian cancer.
Overview
This study investigates the role of Tropomodulin 3 (TMOD3) in ovarian cancer, particularly its association with platinum resistance and immune infiltration. The findings suggest that TMOD3 could be a significant factor in improving therapeutic outcomes for patients with ovarian cancer.
Key Study Components
Area of Science
- Ovarian cancer
- Drug resistance
- Immune response
Background
- Tropomodulin 3 (TMOD3) has been studied in various tumors.
- Previous research has highlighted the role of cytoskeletal proteins in cancer.
- There is limited information on TMOD3's specific role in ovarian cancer.
- Understanding TMOD3's function may provide insights into chemotherapy resistance.
Purpose of Study
- To uncover the role of TMOD3 in ovarian cancer.
- To explore the relationship between TMOD3 expression and platinum resistance.
- To assess the impact of TMOD3 on immune infiltration in ovarian tumors.
Methods Used
- Analysis of TMOD3 expression levels in ovarian cancer samples.
- Correlation studies between TMOD3 expression and chemotherapy resistance.
- Investigation of immune cell infiltration in relation to TMOD3 levels.
- Comparative analysis with existing literature on cytoskeletal proteins.
Main Results
- TMOD3 is highly expressed in ovarian cancer tissues.
- High TMOD3 expression correlates with increased platinum resistance.
- TMOD3 levels are associated with immune cell infiltration in tumors.
- These findings suggest TMOD3's potential as a therapeutic target.
Conclusions
- TMOD3 plays a significant role in ovarian cancer progression.
- Targeting TMOD3 may enhance treatment efficacy in resistant cases.
- Further research is needed to explore TMOD3 as a therapeutic target.
Frequently Asked Questions
Executive Industry Relevance
TMOD3 overexpression has emerged as a molecular marker linked to platinum resistance and immune infiltration in ovarian cancer, directly impacting therapeutic stratification and risk assessment. Integrating TMOD3 expression profiling into discovery-stage workflows can enhance predictive confidence for drug response and inform portfolio triage decisions. This marker's association with survival outcomes positions it as a critical node for mechanistic de-risking in translational oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of TMOD3 as a functional driver of platinum resistance in ovarian cancer models.
- Supports biological de-risking by clarifying TMOD3's role in tumor progression and immune contexture.
- Facilitates predictive confidence in target selection for drug resistance mechanisms.
Screening & Assay Development
- Provides a validated biomarker for stratifying ovarian cancer cell lines by platinum sensitivity.
- Enables quantitative assessment of TMOD3 expression as a readout for compound screening.
- Supports assay standardization for evaluating drug response and immune infiltration signatures.
Translational & Preclinical Research
- Aligns TMOD3 expression with clinical endpoints such as overall and progression-free survival.
- Enables risk-adjusted advancement of candidates targeting platinum-resistant disease subtypes.
- Supports continuity from discovery through preclinical validation by linking molecular markers to patient outcomes.
Pipeline & Workflow Integration
TMOD3 expression analysis integrates into the discovery-to-preclinical continuum, informing both target validation and translational biomarker strategies in ovarian cancer research.
- Discovery Biology: Clarifies the mechanistic link between cytoskeletal regulation and drug resistance.
- Screening: Enables reproducible stratification of cell models for platinum sensitivity using TMOD3 as a quantitative marker.
- Analytics: Provides statistical outputs correlating TMOD3 levels with survival and immune infiltration metrics.
- Translational Research: Connects molecular profiling to clinical risk, supporting biomarker-driven patient selection.
- Enterprise Reuse: Establishes TMOD3 as a reusable marker for resistance and immune contexture across ovarian cancer studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in resistance mechanisms and target validation.
- Operational Value: Standardizes biomarker-driven stratification and assay reproducibility.
- Strategic Value: Informs go/no-go decisions for platinum-based therapy development and patient segmentation.
- Portfolio Impact: Enables risk-adjusted prioritization of assets targeting platinum-resistant ovarian cancer.
Implementation Considerations
- Requires expertise in molecular profiling and bioinformatics analysis of expression datasets.
- Needs access to validated ovarian cancer models and quantitative assay platforms.
- Demands cross-team standardization for TMOD3 measurement and data interpretation.
- Adaptation across diverse ovarian cancer subtypes may require additional validation.
- Dependent on robust statistical analysis to correlate TMOD3 with clinical and immune parameters.
Biopharma FAQs
Chapters in this video
0:00
Introduction
0:51
Analyzing the Expression of TMOD3 in Normal Ovarian Tissues and Ovarian Cancer
2:23
Assessing the Effect of TMOD3 on Overall Survival and Progression‐Free Survival (PFS) in Ovarian Cancer Patients
4:15
TMOD3 Expression Analysis in Platinum‐Based Chemotherapy Resistant and Sensitive Patients and mRNA‐miRNA Analysis
6:56
Checking the Distribution of TMOD3 in Immune Cells and TMOD3 Coexpression Networks in Ovarian Cancer
